Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXEDRINE vs AZASITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Treatment of bacterial conjunctivitis caused by susceptible organisms
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Primarily metabolized by CYP2D6 to 4-hydroxydextroamphetamine, which is further metabolized to various metabolites. Also undergoes deamination and oxidation.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Approximately 16-20% bound; primarily to albumin
~50-60% bound to plasma proteins (primarily albumin).
3.5-4.5 L/kg; indicates extensive tissue distribution, particularly CNS
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
Oral: 75-100% (immediate-release), 70-90% (extended-release); rectal and parenteral routes are not clinically utilized
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
GFR 15–30 m L/min: use with caution, consider dose reduction by 50%. GFR <15 m L/min: not recommended.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
No dosage adjustment required for ophthalmic use.
Age 3–5 years: 2.5 mg orally once daily, increase by 2.5 mg weekly as needed (max 40 mg/day). Age ≥6 years: 5 mg orally once or twice daily, increase by 5 mg weekly (max 40 mg/day).
Safety and efficacy in pediatric patients have not been established; limited data available.
Start at lowest dose (2.5–5 mg orally once daily), titrate slowly; monitor for cardiovascular effects, agitation, and weight loss.
No specific dosage adjustment recommended; use same dosing as for adults.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including DEXEDRINE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
None
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and aggression,Seizures in patients with prior seizure history,Long-term suppression of growth in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when co-administered with serotonergic drugs
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Known hypersensitivity to amphetamine products or other components of DEXEDRINE,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis),Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Avoid high-fat meals with immediate-release formulations as they may delay absorption; for extended-release, high-fat meals can increase peak concentration. Acidic foods (e.g., citrus fruits, fruit juices, carbonated drinks) can reduce absorption. Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate central nervous system stimulation and cardiovascular effects. Maintain adequate hydration. Grapefruit and other CYP2D6 inhibitors may increase effects.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (hyperactivity, irritability, feeding difficulties). Dextroamphetamine is a sympathomimetic amine with potential for vasoconstriction reducing uteroplacental perfusion.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Dextroamphetamine is excreted into breast milk; M/P ratio not established but concentration about 2-7 times maternal plasma. potential for infant stimulation, insomnia, and growth impairment. American Academy of Pediatrics recommends use during breastfeeding only if benefits outweigh risks; monitor infant for agitation and poor weight gain.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and enhanced renal clearance may reduce serum concentrations of dextroamphetamine. Dose adjustment may be necessary based on clinical response; start with lowest effective dose and monitor for worsening ADHD symptoms. Avoid in severe hypertension or preeclampsia.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Monitor for hypertension, tachycardia, and mental status changes (psychosis, mania) especially at high doses. Avoid late-day dosing to prevent insomnia. Use with caution in patients with pre-existing cardiovascular disease or hyperthyroidism. Dextroamphetamine can suppress appetite and cause weight loss; monitor growth in children. Abuse potential is high; schedule II controlled substance. Can precipitate tics in susceptible individuals. Contraindicated within 14 days of MAOIs due to hypertensive crisis.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew the extended-release capsules; swallow whole.,Avoid taking the medication in the evening or close to bedtime to prevent trouble sleeping.,Report any chest pain, shortness of breath, fainting, or rapid heart rate to your doctor immediately.,Contact your doctor if you experience new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,You may experience decreased appetite and weight loss; maintain a healthy diet and inform your doctor if weight loss is significant.,Do not stop taking abruptly; taper dose under medical supervision to avoid withdrawal symptoms.,This medication has potential for abuse and dependence; keep in a safe place and do not share with others.,Avoid alcohol and caffeine as they may increase side effects like jitteriness and heart palpitations.,Tell all healthcare providers you are taking this medication, especially before surgery or dental procedures.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXEDRINE vs AZASITE, answered by our medical review team.
DEXEDRINE is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.. AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXEDRINE and AZASITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXEDRINE is: 5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.. The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXEDRINE and AZASITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXEDRINE is classified as Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of pr. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.